← Leaderboards
Sidney S Negus
Mc Lean Hospital (Belmont, Ma)
$13,528,377
Attributed
$17,992,222
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,992,222 · 10
By mechanism
R01$15,208,045 · 5
P30$1,406,432 · 1
R33$861,479 · 1
P50$272,278 · 1
R61$243,988 · 1
P01$0 · 1
Top collaborators
- Laura J Sim-Selley9 shared
- Richard A Glennon7 shared
- Louis J De Felice6 shared
- Dana E Selley5 shared
- Jose Miguel Eltit1 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsBehavioralProceduresAgonistAnalgesicsPainBehaviorMonoamineNeurochemistryStimulusAreaNucleus AccumbensOpioidSelf AdministrationRewardsSelf StimulationEvaluationBrainClinically RelevantAbsence Of Pain SensationAnimalsReceptorDrug AbuseFunding
Grant awards (55)
A Novel Assay to Improve Translation in Analgesic Drug Development$861,479
R33 · FY2024 · NS · contact PI
Neuropharmacology Core$281,294
P30 · FY2023 · DA · contact PI
A Novel Assay to Improve Translation in Analgesic Drug Development$243,988
R61 · FY2023 · NS · contact PI
Neuropharmacology Core$281,294
P30 · FY2022 · DA · contact PI
Neuropharmacology Core$281,294
P30 · FY2021 · DA · contact PI
Endocannabinoid modulation of pain-depressed behavior$490,537
R01 · FY2020 · DA
Neuropharmacology Core$281,294
P30 · FY2020 · DA · contact PI
Endocannabinoid modulation of pain-depressed behavior$490,537
R01 · FY2019 · DA
Medications Development for Stimulant Abuse$343,125
R01 · FY2019 · DA · contact PI
Neuropharmacology Core$281,256
P30 · FY2019 · DA · contact PI
Medications Development for Stimulant Abuse$62,100
R01 · FY2019 · DA · contact PI
Endocannabinoid modulation of pain-depressed behavior$489,758
R01 · FY2018 · DA
Medications Development for Stimulant Abuse$343,125
R01 · FY2018 · DA · contact PI
Neurobiology and Treatment of Pain$336,000
R01 · FY2018 · NS · contact PI
Endocannabinoid modulation of pain-depressed behavior$534,072
R01 · FY2017 · DA
Medications Development for Stimulant Abuse$343,125
R01 · FY2017 · DA · contact PI
Neurobiology and Treatment of Pain$336,000
R01 · FY2017 · NS · contact PI
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$506,148
R01 · FY2016 · DA
Medications Development for Stimulant Abuse$339,693
R01 · FY2016 · DA · contact PI
Neurobiology and Treatment of Pain$336,000
R01 · FY2016 · NS · contact PI
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$519,371
R01 · FY2015 · DA
Medications Development for Stimulant Abuse$343,125
R01 · FY2015 · DA · contact PI
Neurobiology and Treatment of Pain$336,000
R01 · FY2015 · NS · contact PI
Endocannabinoid modulation of pain-depressed behavior$331,329
R01 · FY2015 · DA · contact PI
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$41,387
R01 · FY2015 · DA
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$580,458
R01 · FY2014 · DA
Neurobiology and Treatment of Pain$349,125
R01 · FY2014 · NS · contact PI
Endocannabinoid modulation of pain-depressed behavior$336,375
R01 · FY2014 · DA · contact PI
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$483,644
R01 · FY2013 · DA
Medications Development for Stimulant Abuse$358,180
R01 · FY2013 · DA · contact PI
Endocannabinoid modulation of pain-depressed behavior$322,920
R01 · FY2013 · DA · contact PI
Neurobiology and Treatment of Pain$312,791
R01 · FY2013 · NS · contact PI
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$55,666
R01 · FY2013 · DA
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERT$501,407
R01 · FY2012 · DA
Medications Development for Stimulant Abuse$373,456
R01 · FY2012 · DA · contact PI
Endocannabinoid modulation of pain-depressed behavior$336,375
R01 · FY2012 · DA · contact PI
Neurobiology and Treatment of Pain$324,136
R01 · FY2012 · NS · contact PI
Medications Development for Stimulant Abuse$373,868
R01 · FY2011 · DA · contact PI
Neurobiology and Treatment of Pain$324,136
R01 · FY2011 · NS · contact PI
Endocannabinoid modulation of pain-depressed behavior$318,555
R01 · FY2011 · DA · contact PI
Medications Development for Stimulant Abuse$397,930
R01 · FY2010 · DA · contact PI
Neurobiology and Treatment of Pain$327,443
R01 · FY2010 · NS · contact PI
Medications Development for Stimulant Abuse$373,750
R01 · FY2009 · DA · contact PI
Neurobiology and Treatment of Pain$334,463
R01 · FY2009 · NS · contact PI
Novel Delta Opioids: Analgesic Effects & Abuse Liability$242,293
R01 · FY2009 · DA · contact PI
Novel Delta Opioids: Analgesic Effects & Abuse Liability$242,293
R01 · FY2008 · DA · contact PI
Novel Delta Opioids: Analgesic Effects & Abuse Liability$241,107
R01 · FY2007 · DA · contact PI
Novel Delta Opioids: Analgesic Effects & Abuse Liability$26,044
R01 · FY2007 · DA · contact PI
Novel Delta Opioids: Analgesic Effects & Abuse Liability$275,130
R01 · FY2006 · DA · contact PI
Novel Delta Opioids: Analgesic Effects &Abuse Liability$281,750
R01 · FY2005 · DA
NOVEL DELTA OPIOIDS--ANALGESIC EFFECTS &ABUSE LIABILITY$200,377
R01 · FY2002 · DA
NEW MEDICIATIONS FOR COCAINE, HEROIN AND POLYDRUG ABUSE$0
P01 · FY2002 · DA
NOVEL DELTA OPIOIDS--ANALGESIC EFFECTS &ABUSE LIABILITY$199,375
R01 · FY2001 · DA
OVARIAN STEROID HORMONE MODULATION OF THE ANALGESIC EFFECTS OF OPIOIDS$272,278
P50 · FY2000 · DA
NOVEL DELTA OPIOIDS--ANALGESIC EFFECTS &ABUSE LIABILITY$193,566
R01 · FY2000 · DA